Scientific Presentations
Preferential Hyperacuity Perimetry Home Monitoring in Patients Following Treatment for Neovascular Age-related Macular Degeneration
Merina Thomas; Shiri Zayit-Soudry; Peggy Orr; Susan B. Bressler; Neil M. BresslerFor patients who had prior anti-VEGF therapy for CNV in which treatment is suspended at a particular visit due to absence of active disease, the preferential hyperacuity perimeter used as a home monitoring device occasionally detected changes warranting resumption of anti-VEGF therapy prior to a routine return visit. However, as a large number of participants had active disease detected at a clinical exam that was not recognized by monitoring, the device would not be acceptable for routine home monitoring in this circumstance without further modification and testing.
FDA Intended Use
ForeseeHome has not been approved by FDA for use other than described in the following Indication for Use: The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration as an aid in monitoring progression of disease factors causing metamorphopsia including, but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.
